Background
Recent studies have reported of an association between Abnormal lipid metabolism and many kind of malignant tumors, and the level of lipid varies with the outcome of the disease. Some data have indicated that the serum level of Apolipoprotein A-I(Apo A-I) in serum was down-regulated in some tumors, but there is few report about it in hodgkin lymphoma. In this study, we aimed to determine the change and clinical significance of serum level Apolipoprotein A-I in hodgkin lymphoma patients.
Methods
A total of 88 newly diagnosed cases of HL were analyzed retrospectively.
Results
Our study showed that the serum level of ApoA-I has significant differences in some clinical features of HL, and it dynamically changed with different stages. Divied patients by whether remission or not, we noticed that the non-remission group had lower ApoA-I than remission group. According the result of multivariate analysis decreased ApoA-I reduction become the independent risk factors of HL. On the basis of Kaplan-Meier survival analysis between high ApoA-I subgroup and low ApoA-I subgroup . we found the lower ApoA-I patients had short OS rate and PFS. The serum ApoA-I level was able to differentiate cases with poor outcomes from cases with good outcomes.
Conclusions
Our results showed that the serum level of ApoA-I was helpful for predicting HL prognosis.